Is the Cx43-specific inhibitor 43Gap26 a relevant therapeutic target in BPD and BPD-PH induced by hyperoxia?

IF 0.5 4区 医学 Q4 RESPIRATORY SYSTEM
C.M. Pilard , L. Gassiat , C. Cardouat , I. Gauthereau , P. Robillard , E. Dumas-de-la-Roque , F. Sauvestre , F. Pelluard , S. Berenguer , L. Sentilhes , F. Coatleven , M. Vincienne , R. Marthan , P. Berger , V. Freund-Michel , C. Guibert
{"title":"Is the Cx43-specific inhibitor 43Gap26 a relevant therapeutic target in BPD and BPD-PH induced by hyperoxia?","authors":"C.M. Pilard ,&nbsp;L. Gassiat ,&nbsp;C. Cardouat ,&nbsp;I. Gauthereau ,&nbsp;P. Robillard ,&nbsp;E. Dumas-de-la-Roque ,&nbsp;F. Sauvestre ,&nbsp;F. Pelluard ,&nbsp;S. Berenguer ,&nbsp;L. Sentilhes ,&nbsp;F. Coatleven ,&nbsp;M. Vincienne ,&nbsp;R. Marthan ,&nbsp;P. Berger ,&nbsp;V. Freund-Michel ,&nbsp;C. Guibert","doi":"10.1016/j.rmr.2025.02.080","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Premature newborns exposed to oxygen are at risk for bronchopulmonary dysplasia (BPD), characterized by lung growth arrest and inflammation. Connexin 43-gap junction (Cx43-GJ) plays a central role in lung development and macrophages-induced inflammation, and is increased by hyperoxia. We thus explored the role of CX43-GJ in experimental BPD.</div></div><div><h3>Methods</h3><div>We used neonatal rats exposed to normoxia or hyperoxia (90% O<sub>2</sub>) and daily treated or not with a specific Cx43 inhibitor (43Gap26) during 14 days. Some experiments were also performed in human fetal pulmonary artery smooth muscle cells (HfPA-SMC) exposed to normoxia or hyperoxia (60% O<sub>2</sub>) and treated or not with 43Gap26 for 2 days.</div></div><div><h3>Results</h3><div>In vivo, we showed that 43Gap26 decreased hyperoxia-induced increased Cx43 expression in lung and improved hypo-alveolarization. However, 43Gap26 did not prevent 1) the hyperoxia-induced alteration of lung function (plethysmographie), 2) the decreased SP-B expression, 3) the disruption of extracellular matrix components (fibronectin and collagen I/III), 4) the increased macrophagic infiltration and M2 polarization, and 5) the increased secretion of pro-inflammatory cytokines (Tissue Inhibitor of Metalloproteinases-1). Furthermore, 43Gap26 blocked the hyperoxia-induced proliferation of type II alveolar epithelial cells, and did not prevent BPD-associated pulmonary hypertension (PH-BPD) or the increased mortality. In vitro, on HfPA-SMC, we confirmed that although an increased Cx43 expression was induced by hyperoxia, 43Gap26 had no effect on the hyperoxia-induced increase of pro-inflammatory cytokines such as IL-6 and Macrophage Inhibitory Factor (MIF). Finally, although we did not demonstrate an increase in oxidative stress in our 2 models, 43Gap26 decreased the hyperoxia-induced increase in heme oxygenase-1 expression in pulmonary arteries.</div></div><div><h3>Conclusion</h3><div>Despite an improved alveolarization in an animal model of hyperoxia-induced BPD, specific inhibition of Cx43 does not appear to be a new potential therapeutic strategy in BPD and PH-BPD as it did not prevent mortality as well as the main hallmarks of BPD and PH-BPD (altered lung function, pulmonary vascular growth arrest and remodeling, inflammation).</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 221"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue des maladies respiratoires","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0761842525001238","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Premature newborns exposed to oxygen are at risk for bronchopulmonary dysplasia (BPD), characterized by lung growth arrest and inflammation. Connexin 43-gap junction (Cx43-GJ) plays a central role in lung development and macrophages-induced inflammation, and is increased by hyperoxia. We thus explored the role of CX43-GJ in experimental BPD.

Methods

We used neonatal rats exposed to normoxia or hyperoxia (90% O2) and daily treated or not with a specific Cx43 inhibitor (43Gap26) during 14 days. Some experiments were also performed in human fetal pulmonary artery smooth muscle cells (HfPA-SMC) exposed to normoxia or hyperoxia (60% O2) and treated or not with 43Gap26 for 2 days.

Results

In vivo, we showed that 43Gap26 decreased hyperoxia-induced increased Cx43 expression in lung and improved hypo-alveolarization. However, 43Gap26 did not prevent 1) the hyperoxia-induced alteration of lung function (plethysmographie), 2) the decreased SP-B expression, 3) the disruption of extracellular matrix components (fibronectin and collagen I/III), 4) the increased macrophagic infiltration and M2 polarization, and 5) the increased secretion of pro-inflammatory cytokines (Tissue Inhibitor of Metalloproteinases-1). Furthermore, 43Gap26 blocked the hyperoxia-induced proliferation of type II alveolar epithelial cells, and did not prevent BPD-associated pulmonary hypertension (PH-BPD) or the increased mortality. In vitro, on HfPA-SMC, we confirmed that although an increased Cx43 expression was induced by hyperoxia, 43Gap26 had no effect on the hyperoxia-induced increase of pro-inflammatory cytokines such as IL-6 and Macrophage Inhibitory Factor (MIF). Finally, although we did not demonstrate an increase in oxidative stress in our 2 models, 43Gap26 decreased the hyperoxia-induced increase in heme oxygenase-1 expression in pulmonary arteries.

Conclusion

Despite an improved alveolarization in an animal model of hyperoxia-induced BPD, specific inhibition of Cx43 does not appear to be a new potential therapeutic strategy in BPD and PH-BPD as it did not prevent mortality as well as the main hallmarks of BPD and PH-BPD (altered lung function, pulmonary vascular growth arrest and remodeling, inflammation).
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revue des maladies respiratoires
Revue des maladies respiratoires 医学-呼吸系统
CiteScore
1.10
自引率
16.70%
发文量
168
审稿时长
4-8 weeks
期刊介绍: La Revue des Maladies Respiratoires est l''organe officiel d''expression scientifique de la Société de Pneumologie de Langue Française (SPLF). Il s''agit d''un média professionnel francophone, à vocation internationale et accessible ici. La Revue des Maladies Respiratoires est un outil de formation professionnelle post-universitaire pour l''ensemble de la communauté pneumologique francophone. Elle publie sur son site différentes variétés d''articles scientifiques concernant la Pneumologie : - Editoriaux, - Articles originaux, - Revues générales, - Articles de synthèses, - Recommandations d''experts et textes de consensus, - Séries thématiques, - Cas cliniques, - Articles « images et diagnostics », - Fiches techniques, - Lettres à la rédaction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信